Last reviewed 2026-04-22 · How we verify

Regeneron Casirivimab + Imdevimab

This combination of two monoclonal antibodies binds to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection of human cells.

This combination of two monoclonal antibodies binds to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection of human cells. Used for COVID-19 (mild to moderate disease in non-hospitalized patients at high risk for progression to severe disease).

At a glance

Mechanism of action

Casirivimab and imdevimab are recombinant human monoclonal antibodies that target non-overlapping epitopes on the spike protein of SARS-CoV-2. By binding to the spike protein, they prevent the virus from attaching to and entering human cells, thereby neutralizing viral infectivity. The combination approach reduces the risk of viral escape mutants.

Approved indications

• COVID-19 (mild to moderate disease in non-hospitalized patients at high risk for progression to severe disease)

Common side effects

• Infusion-related reactions
• Hypersensitivity reactions
• Fever
• Chills

Key clinical trials

• UPMC OPTIMISE-C19 Trial, a COVID-19 Study (PHASE4)
• Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Regeneron Casirivimab + Imdevimab CI brief — competitive landscape report
• Regeneron Casirivimab + Imdevimab updates RSS · CI watch RSS
• Erin McCreary portfolio CI